Emerging therapeutic options for periorbital and orbital cutaneous basal and squamous cell carcinomas

References

• Tyers AG. Orbital exenteration for invasive skin tumors. Eye. 2006;20(10):1165–1170. doi:10.1038/sj.eye.6702380.
   PubMed Web of Science ®Google Scholar
• Nagendran ST, Lee NG, Fay A, Lefebrvre DR, Sutula FC, Freitag SK. Orbital exenteration: the 10-year Massachusetts eye and ear infirmary experience. Orbit. 2016;35(4):199–206. doi:10.1080/01676830.2016.1176210.
   PubMed Web of Science ®Google Scholar
• Rabey N, Abood A, Gillespie P, Athanassoglou V, Rene C, Malata CM. Reconstruction of complex orbital exenteration defects: a single center’s experience with a five year follow-up. Ann Plast Surg. 2014;73(2):158–163. doi:10.1097/SAP.0b013e31826a1a56.
   PubMed Web of Science ®Google Scholar
• Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152(5):939–947. doi:10.1111/j.1365-2133.2005.06486.x.
   PubMed Web of Science ®Google Scholar
• Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol. 2003;139(10):1325–1332. doi:10.1001/archderm.139.10.1325.
   PubMed Web of Science ®Google Scholar
• Choontanom R, Thanos S, Busse H, Stupp T. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefe’s Arch Clin Exp Ophthalmol. 2007;245:1217–1220.
   PubMed Web of Science ®Google Scholar
• Carneiro RC, Santiago de Maceido EM, Matayoshi S. Imiquimod 5% cream for the treatment of periocular basal cell carcinoma. Ophthal Plast Reconstr Surg. 2010;26(2):100–102. doi:10.1097/IOP.0b013e3181b8dd71.
   PubMed Web of Science ®Google Scholar
• Garcia-Martin E, Idoipe M, Gil LM, et al. Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas. J Ocular Pharm Ther. 2010;26(4):373–379. doi:10.1089/jop.2010.0030.
   PubMed Web of Science ®Google Scholar
• Prokosch V, Thanos S, Spaniol K, Stupp T. Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids. Graefes Arch Clin Exp Ophthalmol. 2011;249(1):121–125. doi:10.1007/s00417-010-1526-3.
   PubMed Web of Science ®Google Scholar
• Singh M, Singh H, Kakkar N, Zadeng Z, Gupta P. Treatment of squamous cell carcinoma of the eyelid with imiquimod 5% cream. Can J Ophthalmol. 2019;54(1):e24–27. doi:10.1016/j.jcjo.2018.03.010.
   PubMed Web of Science ®Google Scholar
• Pak E, Segal RA. Hedgehog signal transduction: key players, oncogenic drivers, and cancer therapy. Dev Cell. 2016;38:333–344.
   PubMed Web of Science ®Google Scholar
• Gutzmer R, Solomon JA. Hedgehog pathway inhibition for the treatment of basal cell carcinoma. Target Oncol. 2019;14:253–267.
   PubMed Web of Science ®Google Scholar
• Peris K, Licitra L, Ascierto PA, et al. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. Front Oncol. 2015;11(4):703–712. doi:10.2217/fon.14.281.
   Google Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal cell carcionma. N Eng J Med. 2012;366(23):2171–2179. doi:10.1056/NEJMoa1113713.
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332.
   PubMedGoogle Scholar
• Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–728.
   PubMed Web of Science ®Google Scholar
• Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018;32(3):372–381.
   PubMed Web of Science ®Google Scholar
• Gill HS, Moscato EE, Chang ALS, Soon S, Silkiss RZ. Vismodegib for periocular and orbital basal cell carcinoma. JAMA Ophthalmol. 2013;131(12):1591–1594. doi:10.1001/jamaophthalmol.2013.5018.
   PubMed Web of Science ®Google Scholar
• DeMirci H, Worden F, Nelson CC, Elner VM, Kahana A. Efficacy of vismodegib (ErivedgeTM) for basal cell carcinoma involving the orbit and periocular area. Ophthal Plast Reconstr Surg. 2015;31:463–466.
   PubMed Web of Science ®Google Scholar
• Sagiv O, Nagarajan P, Ferrarotto R, et al. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. Br J Ophthalmol. 2019;103(6):775–780. doi:10.1136/bjophthalmol-2018-312277.
   PubMed Web of Science ®Google Scholar
• Sagiv O, Ding S, Ferraotto R, et al. Impact of Food and Drug Administration approval of vismodegib on prevalence of orbital exenteration as a necessary surgical treatment for locally advanced periocular basal cell carcinoma. Ophthalmic Plast Reconstr Surg. 2019;35(4):350–353. doi:10.1097/IOP.0000000000001251.
   PubMed Web of Science ®Google Scholar
• Eiger-Moscovich M, Reich E, Tauber E, et al. Efficacy of vismodegib for the treatment of orbital and advanced periocular basal cell carcinoma. Am J Ophthalmol. 2019;207:62–70.
   PubMed Web of Science ®Google Scholar
• DeGiorgi V, Trane L, Pieretti G, et al. Treatment of periocular advanced basal cell carcinoma with Hedgehog pathway inhibitors: a single-center study and a new dedicated therapeutic protocol. Dermatol Rep. 2021;13:9240.
   PubMedGoogle Scholar
• Dummer R, Ascierto PA, Basset-Seguin N, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venerol. 2020;34(9):1944056. doi:10.1111/jdv.16230.
   Web of Science ®Google Scholar
• Davis CM, Lewis KD. Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: pD-1 strikes again. Ther Adv Med Oncol. 2022;14:1–5.
   Google Scholar
• Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148(11):1324–1325. doi:10.1001/archdermatol.2012.2354.
   PubMedGoogle Scholar
• Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26(1):677–704. doi:10.1146/annurev.immunol.26.021607.090331.
   PubMed Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. The EMBO Journal EMBO Journal. 1992;11(11):3887–3895. doi:10.1002/j.1460-2075.1992.tb05481.x.
   PubMed Web of Science ®Google Scholar
• Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023–5039.
   PubMed Web of Science ®Google Scholar
• Toh JW, de Souza P, Lim SH, et al. The potential value of immunotherapy in colorectal cancers: review of the evidence for programmed death-1 inhibitor therapy. Clin Colorectal Cancer. 2016;15(4):285–291. doi:10.1016/j.clcc.2016.07.007.
   PubMed Web of Science ®Google Scholar
• Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.
   PubMed Web of Science ®Google Scholar
• Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767–1778.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Lilo MT, Ogurtsova A, et al. Basal cell carcinoma: pD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Canc. 2017;5(1):23. doi:10.1186/s40425-017-0228-3.
   PubMedGoogle Scholar
• Chang ALS, Tran DC, Cannon JGD, et al. Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study. J Am Acad Dermatol. 2019;80(2):564–566.
   PubMed Web of Science ®Google Scholar
• Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancel Oncol. 2021;22:848–857.
   PubMedGoogle Scholar
• Wladis EJ, Lee JA, Carlson JA, Martino N, Adam AP. Programmed death-1 pathway in orbital invasion of cutaneous carcinomas. Ophthalmic Plast Reconstr Surg. 2018;34:110–113.
   PubMed Web of Science ®Google Scholar
• Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–351. doi:10.1056/NEJMoa1805131.
   PubMed Web of Science ®Google Scholar
• Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21(2):294–305.
   PubMed Web of Science ®Google Scholar
• Maubec E, Boubaya M, Petrow P, et al. Phase Ii study of pembrolizumab as first-line, single- drug therapy for patients with unresectable cutaneous squamous cell carcinomas. JCO. 2020;38(26):3051–3061.
   PubMed Web of Science ®Google Scholar
• Pickering CR, Zhou JH, Lee JJ, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014;20(24):6582–6592.
   PubMed Web of Science ®Google Scholar
• Hughes BGM, Munz-Couselo E, Mortier L, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Annals Oncol. 2021;32(10):1276–1285. doi:10.1016/j.annonc.2021.07.008.
   PubMed Web of Science ®Google Scholar
• Hughes BGM, Mendoza RG, Basset-Seguin N, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Dermatol Ther (Heidelb). 2021;11:1777–1790.
   PubMed Web of Science ®Google Scholar
• Zhu H, Lewis DJ. Topical hedgehog inhibitors for basal cell carcinoma: how far away are we? Exp Opin Pharmacother. 2022;23(6):739–740. doi:10.1080/14656566.2022.2050215.
   PubMed Web of Science ®Google Scholar
• Lajoie JE, Lau KW, Adam AP, Wladis EJ. Cytotoxic T-lymphocyte-associated protein-4 and lymphocyte activation gene-3 expression in orbitally-invasive versus nodular basal cell carcinoma. Ophthalmic Plast Reconstr Surg. 2021;37(3S):109–111. doi:10.1097/IOP.0000000000001853.
   Google Scholar
• Mohan SV, Kuo KS, Chang ALS. Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma. JAAD Case Rep. 2016;2(1):13–15. doi:10.1016/j.jdcr.2015.11.007.
   PubMedGoogle Scholar
• Wladis EJ, Weller B, Adam AP. CD73 is enriched in cutaneous carcinomas that invade the orbit. Ophthalmic Plast Reconstr Surg. 2020;36(3):247–249. doi:10.1097/IOP.0000000000001520.
   PubMed Web of Science ®Google Scholar
• Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Hasko G. Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer. 2016;2(2):95–109. doi:10.1016/j.trecan.2016.01.003.
   PubMed Web of Science ®Google Scholar